Reports on research progress of mantle cell lymphoma in the 55th ASH annual meeting / 白血病·淋巴瘤

ABSTRACT

Mantle cell lymphoma (MCL),as a kind of highly aggressive non-Hodgkin's lymphoma,is characterized by malignant B cell infiltration of lymph node,gastrointestinal tract and bone marrow.Patients suffering from MCL are prone to drug resistance or progression of disease.The 55th ASH annual meeting about MCL explored all aspects.In preclinical research aspectsnew mutations including ATM,POT1 and tumor microenvironment further improved the pathogenesis mechanism of MCL.In prognostic indicators,minimal residual disease detected by molecular techniques and whole genome methylation analysis provided new tools for monitoring MCL prognosis and curative effect to guide further risk stratification and individual treatment.Exploration of high effective and low toxic side effective treatment strategies for elderly MCL patients has become a major focus of the meeting.Chemoimmunotherapy including Lenalidomide,bendamustine,rituximab and autologous stem cell transplantation provide more options for the treatment of elderly MCL patients.Novel drugs such as ibrutinib,ABT-199 and MLN8237 have shown encouraging results in preclinical trials which provide new hope for MCL patients.